Mr. David J. Main
President & CEO
Mr. Main has over 25 years experience in the pharmaceutical industry and brings a demonstrated ability to grow and finance pharmaceutical development companies. As a co-founder of Aquinox, Mr. Main has overseen the advancement of the Company’s lead product, AQX-1125, from a target validation program to now entering Phase 3 studies. During this time he has also been responsible for the transition of Aquinox from a private to a NASDAQ-listed public company with over US$200 million raised to date in equity capital. Mr. Main was formerly the President and CEO of INEX Pharmaceuticals Corp. and, prior to INEX, was Vice President at QLT Inc., one of Canada’s inaugural biotech companies. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). Mr. Main formerly served as the Chair of LifeSciences BC (formerly BC Biotech), is currently the Chair of BIOTECanada and a Director of BIO.org as well he also serves on a number of private and not-for-profit Boards.
Mr. Kamran Alam
VP Finance & Chief Financial Officer
Mr. Alam has over 15 years' experience in the pharmaceutical industry and brings a demonstrated ability to finance and identify strategic opportunities for biotechnology companies. Mr. Alam was most recently the Senior Director, Business Development of Sirius Genomics where he worked directly with the CEO playing a lead role in planning and executing the company's business and financial strategy. Previously he has held senior business roles at the Centre for Drug Research and Development (CDRD), Angiotech Pharmaceuticals and AnorMED. Mr. Alam started his career as a Chartered Accountant with PriceWaterhouseCoopers (PWC) as a member of their Life Sciences Practice and gained valuable experience in the financing, auditing and tax structuring of a number of biotechnology and technology companies. Mr. Alam's diverse industry experience has provided him with an opportunity to participate in numerous and varied finance transactions, partnering deals and mergers and acquisitions in the U.S.A., Canada, Europe, and Asia. In addition to his CA designation, Mr. Alam possesses an MBA in International Business and Strategy from the University of Victoria as well as a B.Sc. in Cell Biology and Genetics from the University of British Columbia.
Dr. David Green
VP, Global Clinical Operations
Dr. Green has over 21 years of clinical trial operations experience in academic, bio-pharmaceutical, and CRO settings. Most recently, Dr. Green was Executive Director at United Therapeutics leading global clinical operations for developmental drug candidates targeting orphan disease indications. Prior to that he was the Vice President of Global Clinical Operations & Biometrics at ReSearch Pharmaceutical Services, Executive Director of Clinical Operations at Amgen, and Clinical Program Manager at Abbott Labs. Dr. Green has a diverse set of global clinical operations experiences across multiple therapeutic areas. He brings a depth of experience in the development, implementation, execution, and management of clinical trial operations and clinical drug development in all Phases of clinical development.
Mr. Lloyd Mackenzie
VP, Technical Operations
Mr. Mackenzie joined Aquinox in May 2008 and was recently promoted to Vice President in May of 2013. Responsible for the company's Research and Development activities, Mr. Mackenzie has over 12 years of experience in the biopharmaceutical industry with expertise in medicinal chemistry, biochemistry and CMC. He is the author of 15 scientific publications and is an inventor on four patents. Prior to joining Aquinox, Mr. Mackenzie was a Research Scientist for Pharmaceutical Development at QLT Inc.. Prior to that, Mr. Mackenzie was a Research Scientist at Inflazyme Pharmaceuticals Inc.
Ms. Shelley McCloskey
VP, Human Resources & Administration
Ms. McCloskey has over 15 years of human resources leadership experience in the health industry. Most recently, Ms. McCloskey was Vice President, Human Resources at Stemcell Technologies Inc. (Stemcell), Canada's largest life sciences company by number of employees, with operations in North America, Europe and Asia Pacific. Prior to joining Stemcell in 2010, Ms. McCloskey was Vice President, Human Resources at Xantrex Technology Inc., a publically traded global advanced renewable energy and power electronics company acquired by Schneider Electric for C$500M in 2008. From 2000 to 2005, Ms. McCloskey served as Vice President, Human Resources and Information Systems at Inex Pharmaceuticals Inc. helping that Company grow from 40 to 225 employees.
Mr. David Mitchell
VP, Global Regulatory Affairs & Quality Assurance
Mr. Mitchell brings to Aquinox over 30 years regulatory experience including negotiations with the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), facilitating new drug and biologics development and approvals. Previously, Mr. Mitchell led global regulatory strategy in oncology, immunology, and neuroscience development at AbbVie, Inc. (North Chicago, IL), Biogen Idec (San Diego, CA), Bayer AG (Leverkusen, Germany), and The Upjohn Company (Kalamazoo, MI). Additionally, he was responsible for building the Regulatory and Quality infrastructure at several small biotechs in the United States. He presently serves on the Global Committee of The Food and Drug Law Institute (Washington, D.C.) where he provides advice on program and policy development in global food and drug law. Mr. Mitchell holds a M.Sc. degree in Bioscience Regulatory Affairs from The Johns Hopkins University (Baltimore, MD) and a BS in Chemistry degree from Mississippi College (Clinton, MS).
Dr. Stephen Shrewsbury, M.D.
SVP, Clinical Development & Chief Medical Officer
Dr. Shrewsbury was most recently Senior Vice President, Preclinical & Clinical Development and Chief Medical Officer of AVI BioPharma (now Sarepta Therapeutics). From 2005 until 2009, he held similar roles at Adamas Pharmaceuticals and MAP Pharmaceuticals. While at MAP, Dr. Shrewsbury lead four inhaled drug programs and took two lead candidates (in asthma and migraine) from preclinical stage to Phase III in 18 months. Prior to his experience in biotechnology, Dr. Shrewsbury spent 10 years with Glaxo and Chiron launching notable respiratory programs such as Seretide in Europe and Flovent and Advair in the US. Dr. Shrewsbury received his medical degree from the University of Liverpool, UK and spent 13 years working in the UK National Health Service before entering the pharmaceutical industry.